Stockreport

KROS Stock: What to Know About Rinvatercept in DMD [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company [Read more]